Chinese Chemical Letters
|
2025, 36(2): 110545
Corrigendum to "An overview of polymeric nanomicelles in clinical trials and on the market" [Chinese Chemical Letters 32 (2021) 243-257]
Full
- a Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, China
- b Laboratory for Marine Drugs and Bioproducts of Qingdao National Laboratory for Marine Science and Technology, Qingdao 266237, China
- c Shandong Center for Food and Drug Evaluation and Certification, Ji'nan 250013, China
Xue Zheng, Jizhen Xie, Xing Zhang, Weiting Sun, Heyang Zhao, Yantuan Li, Cheng Wang.
Corrigendum to "An overview of polymeric nanomicelles in clinical trials and on the market" [Chinese Chemical Letters 32 (2021) 243-257][J].
Chinese Chemical Letters,
2025
, 36
(2)
: 110545
-
.
DOI: 10.1016/j.cclet.2024.110545
The authors regret <According to ref. [90], the sentence on page 249 "A Phase Ⅰ/Ⅱ trial of NC-6004 plus gemcitabine for metastatic pancreatic cancer was conducted in Taiwan and Singapore (n = 22) [90]." should be revised to "A Phase Ⅰ/Ⅱ trial of NC-6004 plus gemcitabine for metastatic pancreatic cancer was conducted in the United States and Europe (n = 22) [90].">.
The authors would like to apologise for any inconvenience caused.